Get the Daily Brief
Latest Biotech News
FDA Suspends Valneva’s Chikungunya Vaccine License Amid Safety Concerns
The U.S. Food and Drug Administration (FDA) has suspended the license of Valneva’s chikungunya vaccine, Ixchiq, due to recent reports of serious adverse events consistent with chikungunya-like...
Massachusetts Biotech Funding Plummets Amidst Federal Uncertainty
The Massachusetts biotech industry faces a challenging year as both public and private funding decline sharply. Venture capital investment dropped over 17% to $2.75 billion in the first half of...
Ultrasound Technology Activates Drugs to Target Pancreatic Cancer
Researchers at the HonorHealth Research Institute have developed a novel approach that combines chemotherapeutic agents with innovative ultrasound technology to activate drugs specifically in...
Deep Learning Framework D-S-Net Enhances Lung Tumor Segmentation Accuracy
A breakthrough in medical imaging, the D-S-Net deep learning framework significantly improves precision in lung cancer tumor boundary delineation, facilitating better Gross Tumor Volume (GTV)...
AI Model DeepMVP Reveals How Protein Modifications Link Mutations to Disease
Scientists at Baylor College of Medicine have developed DeepMVP, an artificial intelligence model that predicts sites of post-translational modifications (PTMs) in proteins and how genetic...
AbbVie Buys Psychedelic Depression Drug: $1.2 Billion Deal
AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead psychedelic candidate bretisilocin for up to $1.2 billion. Bretisilocin, a 5-HT2A receptor agonist with promising phase IIa results in...
First Pig-to-Human Lung Transplant Shows Nine Days Function
A pioneering xenotransplantation case saw a genetically modified pig lung transplanted into a brain-dead human remain viable for nine days. Despite no hyperacute rejection due to alpha-gal...
FDA Suspends License for Valneva Chikungunya Vaccine
The US FDA has suspended the biologics license for Valneva’s live-attenuated chikungunya virus vaccine, Ixchiq, citing serious adverse events consistent with chikungunya-like illness and at least...
Lilly’s Oral GLP-1 Pill Orforglipron Hits Weight Loss and Diabetes Trial Goals
Eli Lilly reported positive phase III results for orforglipron, an oral GLP-1 receptor agonist addressing obesity and type 2 diabetes. The phase III Attain-2 trial demonstrated significant weight...
Regeneron’s RNAi Drug Cemdisiran Meets Phase III Goals for Myasthenia Gravis
Regeneron's RNA interference therapy cemdisiran, licensed from Alnylam, achieved success in pivotal phase III trials in generalized myasthenia gravis (MG). The siRNA agent, as monotherapy, showed...
Akeso Reports Survival Benefits in Lung Cancer Trials
Chinese biotech Akeso disclosed that its PD-1xVEGF bispecific antibody ivonescimab significantly improved overall survival as second-line therapy combined with chemotherapy in advanced non-small...
Massachusetts Biotech Sector Faces Funding Decline Amid Uncertain Federal Policy
MassBio’s latest industry report details a significant downturn in biotech funding within Massachusetts, with venture capital investments dropping over 17% in H1 2025 compared to 2024, reaching...
New AI Tools Advance Cancer Tissue Imaging and Analysis
Mount Sinai and Virginia Commonwealth University researchers have introduced AI-powered platforms—MARQO and Vesalius—that significantly enhance cancer tissue examination and spatial cellular...
Lund University Reveals Functional Role of Repetitive DNA in Human Brain Development
A novel study from Lund University challenges the notion of 'junk DNA' by demonstrating active functional roles for repetitive DNA sequences during early human brain development. Employing...
AbbVie Acquires Gilgamesh’s Psychedelic Depression Drug in $1.2 Billion Deal
AbbVie has agreed to buy Gilgamesh Pharmaceuticals’ lead psychedelic candidate bretisilocin (GM-2505), targeting moderate-to-severe major depressive disorder, for up to $1.2 billion. Bretisilocin...
Regeneron’s Cemdisiran Meets Phase III Endpoints in Myasthenia Gravis
Regeneron Pharmaceuticals, licensing cemdisiran from Alnylam, announced successful pivotal trial results of the siRNA drug in generalized myasthenia gravis. The monotherapy reduced complement...
Lilly’s Oral GLP-1 Pill Shows Significant Weight Loss in Diabetes and Obesity Trials
Eli Lilly reported positive Phase III results from its oral GLP-1 receptor agonist orforglipron, demonstrating statistically significant weight loss and blood sugar reductions in adults with...
FDA Suspends Valneva’s Chikungunya Vaccine License
The U.S. FDA suspended the biologics license for Valneva’s chikungunya vaccine Ixchiq following reports of serious adverse events, including chikungunya-like illness in recipients. The suspension...
Breakthrough in Pig-to-Human Lung Xenotransplantation Lasting Nine Days
Scientists achieved the first pig-to-human lung transplant with a genetically modified pig lung remaining viable and functional for nine days in a brain-dead human recipient. The transplanted...
Massachusetts Biotech Industry Faces Sharp Funding Decline Amid Uncertainty
The annual MassBio report paints a grim picture with public and private funding in Massachusetts biotech plunging. Venture capital investment dropped over 17% to $2.75 billion, the lowest since...